"Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when ..."

Benyamin Grosman et al. (2021)

> Home

Details and statistics

DOI: 10.1016/J.CMPB.2021.106087

access: closed

type: Journal Article

metadata version: 2022-08-16

- view
  - electronic edition via DOI
  - unpaywalled version
  authority control:
- export record
  dblp key:
  - journals/cmpb/GrosmanWPRVKSCE21
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/journals/cmpb/GrosmanWPRVKSCE21
Benyamin Grosman, Di Wu, Neha Parikh, Anirban Roy, Gayane Voskanyan, Natalie Kurtz, Jeppe Sturis, Ohad Cohen, Magnus Ekelund, Robert A. Vigersky:
Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed^TM 670G hybrid closed-loop system in simulated trials compared to NovoLog®. Comput. Methods Programs Biomed. 205: 106087 (2021)

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.